Search

everythinglearnresearchcommunity

for

Search:↓

Finasteride use is not clearly linked to an increased risk of male breast cancer.

Some breast cancer treatments cause hair loss similar to male pattern baldness, which can be improved with minoxidil.

Taking 5-alpha reductase inhibitors does not increase the risk of breast cancer in men.

A breast cancer patient had lasting hair loss after chemotherapy, which improved with minoxidil treatment.

The number of advanced breast cancer cases in women under 40 has increased, but the overall numbers are still low.

Some breast cancer treatments, like taxanes, can cause long-term hair loss.

Patients with advanced breast cancer and high hormone receptor levels who had surgery for ovarian/pelvic metastases lived longer, especially if they had high estrogen receptor levels.

A man developed male breast cancer after four years of finasteride treatment for an enlarged prostate.

Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.

An 86-year-old man with prostate cancer was diagnosed with a rare, low-grade breast cancer and underwent surgery but declined additional hormone therapy.

Understanding breast cancer requires considering both medical advancements and social influences.

Some early breast cancer patients have long-term hair loss after chemotherapy, especially older and postmenopausal women.

Enobosarm may effectively treat androgen receptor-positive breast cancer with fewer side effects.

After chemotherapy for early breast cancer, 33.4% of patients had long-term significant hair loss, with some hair regrowth over time, but treatments for hair loss were largely ineffective.

Docetaxel and paclitaxel for breast cancer can cause permanent, severe hair loss.

Hair from breast cancer patients shows changes in structure and composition, and a test using these changes detected cancer but also falsely identified some healthy samples as cancerous.

X-ray diffraction of hair might help detect breast cancer non-invasively.

ADCs can effectively treat breast cancer but may cause side effects like nausea and hair loss.

Multimodal primary treatment improves survival in premenopausal breast cancer patients and is also beneficial for postmenopausal women.

Certain gene patterns in breast cancer are linked to how active hormone receptors are and could affect patient survival.

Research from 2011 to 2020 shows androgen receptors could be key for prognosis and treatment in certain breast cancers.

Minoxidil and ranolazine together can reduce the spread of certain breast cancer cells.

Electric pulse treatments for breast cancer show promise in being safer and more effective, with fewer side effects.

The conclusion is that thorough investigation of hypertension and hormonal dysfunctions is important, and there may be a link between these conditions and cancer.

The paper concludes that breast cancer treatment involves complex interactions between medical symptoms, patient experiences, and commercial influences, requiring a holistic approach.

Radiation therapy in breast cancer patients changes gene expression related to DNA damage, fibroblast growth, and hair follicle development, which could help improve treatment for radiation-induced fibrosis.

Docetaxel treatment for breast cancer can cause permanent hair loss.

Taking 5-alpha reductase inhibitors might be linked to breast cancer in men.

Scalp cooling is largely ineffective in preventing hair loss from breast cancer chemotherapy.

Taking 5α-reductase inhibitors does not significantly increase the risk of breast cancer in men.